A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

Penny A. Dacks; Joshua J. Armstrong; Stephen K. Brannan; Aaron J. Carman; Allan M. Green; M. Sue Kirkman; Lawrence R. Krakoff; Lewis H. Kuller; Lenore J. Launer; Simon Lovestone; Elizabeth Merikle; Peter J. Neumann; Kenneth Rockwood; Diana W. Shineman; Richard G. Stefanacci; Priscilla Velentgas; Anand Viswanathan; Rachel A. Whitmer; Jeff D. Williamson; Howard M. Fillit

doi:10.1186/s13195-016-0200-3

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

Penny A. Dacks, Joshua J. Armstrong, Stephen K. Brannan, Aaron J. Carman, Allan M. Green, M. Sue Kirkman, Lawrence R. Krakoff, Lewis H. Kuller, Lenore J. Launer, Simon Lovestone, Elizabeth Merikle, Peter J. Neumann, Kenneth Rockwood, Diana W. Shineman, Richard G. Stefanacci, Priscilla Velentgas, Anand Viswanathan, Rachel A. Whitmer, Jeff D. Williamson, Howard M. Fillit

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

11 Citas (Scopus)

Resumen

Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.

Idioma original	English
Número de artículo	200
Publicación	Alzheimer's Research and Therapy
Volumen	8
N.º	1
DOI	https://doi.org/10.1186/s13195-016-0200-3
Estado	Published - ago. 20 2016

Nota bibliográfica

Funding Information:
This position paper and the corresponding advisory panel were funded by the Alzheimer’s Drug Discovery Foundation. Support for authors’ time was provided by the Canadian Consortium on Neurodegeneration in Aging (JJA); the Intramural Research Program, National Institute on Aging, NIH (LJL); NIH-NIA grants K23 AG028726 and R01AG047975 (AV). Takeda Pharmaceuticals provided some support for the advisory panel; the American Heart Association supported the cost of travel for their representative (AV).

Publisher Copyright:
© 2016 The Author(s).

ASJC Scopus Subject Areas

Neurology
Clinical Neurology
Cognitive Neuroscience

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1186/s13195-016-0200-3

Otros archivos y enlaces

Citar esto

Dacks, P. A., Armstrong, J. J., Brannan, S. K., Carman, A. J., Green, A. M., Kirkman, M. S., Krakoff, L. R., Kuller, L. H., Launer, L. J., Lovestone, S., Merikle, E., Neumann, P. J., Rockwood, K., Shineman, D. W., Stefanacci, R. G., Velentgas, P., Viswanathan, A., Whitmer, R. A., Williamson, J. D., & Fillit, H. M. (2016). A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. Alzheimer's Research and Therapy, 8(1), Artículo 200. https://doi.org/10.1186/s13195-016-0200-3

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. / Dacks, Penny A.; Armstrong, Joshua J.; Brannan, Stephen K. et al.
En: Alzheimer's Research and Therapy, Vol. 8, N.º 1, 200, 20.08.2016.

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

Dacks, PA, Armstrong, JJ, Brannan, SK, Carman, AJ, Green, AM, Kirkman, MS, Krakoff, LR, Kuller, LH, Launer, LJ, Lovestone, S, Merikle, E, Neumann, PJ, Rockwood, K, Shineman, DW, Stefanacci, RG, Velentgas, P, Viswanathan, A, Whitmer, RA, Williamson, JD & Fillit, HM 2016, 'A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline', Alzheimer's Research and Therapy, vol. 8, n.º 1, 200. https://doi.org/10.1186/s13195-016-0200-3

@article{a3200cfb96684074a5addc6da861a87e,

title = "A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline",

abstract = "Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.",

author = "Dacks, {Penny A.} and Armstrong, {Joshua J.} and Brannan, {Stephen K.} and Carman, {Aaron J.} and Green, {Allan M.} and Kirkman, {M. Sue} and Krakoff, {Lawrence R.} and Kuller, {Lewis H.} and Launer, {Lenore J.} and Simon Lovestone and Elizabeth Merikle and Neumann, {Peter J.} and Kenneth Rockwood and Shineman, {Diana W.} and Stefanacci, {Richard G.} and Priscilla Velentgas and Anand Viswanathan and Whitmer, {Rachel A.} and Williamson, {Jeff D.} and Fillit, {Howard M.}",

note = "Funding Information: This position paper and the corresponding advisory panel were funded by the Alzheimer{\textquoteright}s Drug Discovery Foundation. Support for authors{\textquoteright} time was provided by the Canadian Consortium on Neurodegeneration in Aging (JJA); the Intramural Research Program, National Institute on Aging, NIH (LJL); NIH-NIA grants K23 AG028726 and R01AG047975 (AV). Takeda Pharmaceuticals provided some support for the advisory panel; the American Heart Association supported the cost of travel for their representative (AV). Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = aug,

day = "20",

doi = "10.1186/s13195-016-0200-3",

language = "English",

volume = "8",

journal = "Alzheimer's Research and Therapy",

issn = "1758-9193",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

AU - Dacks, Penny A.

AU - Armstrong, Joshua J.

AU - Brannan, Stephen K.

AU - Carman, Aaron J.

AU - Green, Allan M.

AU - Kirkman, M. Sue

AU - Krakoff, Lawrence R.

AU - Kuller, Lewis H.

AU - Launer, Lenore J.

AU - Lovestone, Simon

AU - Merikle, Elizabeth

AU - Neumann, Peter J.

AU - Rockwood, Kenneth

AU - Shineman, Diana W.

AU - Stefanacci, Richard G.

AU - Velentgas, Priscilla

AU - Viswanathan, Anand

AU - Whitmer, Rachel A.

AU - Williamson, Jeff D.

AU - Fillit, Howard M.

N1 - Funding Information: This position paper and the corresponding advisory panel were funded by the Alzheimer’s Drug Discovery Foundation. Support for authors’ time was provided by the Canadian Consortium on Neurodegeneration in Aging (JJA); the Intramural Research Program, National Institute on Aging, NIH (LJL); NIH-NIA grants K23 AG028726 and R01AG047975 (AV). Takeda Pharmaceuticals provided some support for the advisory panel; the American Heart Association supported the cost of travel for their representative (AV). Publisher Copyright: © 2016 The Author(s).

PY - 2016/8/20

Y1 - 2016/8/20

N2 - Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.

AB - Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.

UR - http://www.scopus.com/inward/record.url?scp=84982290289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982290289&partnerID=8YFLogxK

U2 - 10.1186/s13195-016-0200-3

DO - 10.1186/s13195-016-0200-3

M3 - Review article

C2 - 27543171

AN - SCOPUS:84982290289

SN - 1758-9193

VL - 8

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

IS - 1

M1 - 200

ER -

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto